It was a pleasure to speak with Dr Lynda Grine (Ghent University Hospital, Ghent, Belgium) about her research into the effects of intermittent fasting on psoriasis.
Her presentation entitled ‘Interim results of the MANGO trial: effects of modified intermittent fasting in psoriasis’ was presented at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us a brief overview of the comorbidities, including metabolic syndrome and leaky gut syndrome, associated with psoriasis? (0:05)
- What is the rationale for intermittent fasting in psoriasis patients? (1:19)
- Could you tell us a little about the MANGO trial protocol? (3:21)
- When will the results be available? (4:47)
Disclosures: Dr Lynda Grine has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Linda Stein Gold, EADV 2022: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2
PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!